Brief: Biogen Says Co Received European Commission Approval For High Dose Regimen Of SPINRAZA
12/01/2026 16:13
Jan 12 (Reuters) - Biogen Inc BIIB.O: BIOGEN RECEIVES EUROPEAN COMMISSION APPROVAL FOR HIGH DOSE REGIMEN OF SPINRAZA® (NUSINERSEN) FOR SPINAL MUSCULAR ATROPHY BIOGEN - HIGH DOSE SPINRAZA APPROVED IN JAPAN, DECISION EXPECTED BY APRIL 3, 2026 Source text: ID:nGNX2Kn9Sk Further company coverage: BIIB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study